Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3617 in Advanced Malignant Tumors
NCT05110807Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3617 in cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum tolerated dose at 48 weeks and Adverse events and serious adverse events at 48 weeks. Status: unknown.
02
Drugs
TQB3617
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05110807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05110807.